News

The Manila Times
manilatimes. net > 04/15/2026 > tmt-newswire > globenewswire > comprehensive-healthcare-launches-just-in-time-prescriber-scheduling-to-improve-access-to-behavioral-health-medication-services > 2320329

Comprehensive Healthcare Launches 'Just In Time" Prescriber Scheduling to Improve Access to Behavioral Health Medication Services

6+ hour, 2+ min ago  (261+ words) New model helps clients schedule prescriber appointments within days Under the Just In Time model, appointments are scheduled closer to the date of service rather than weeks in advance. Scheduling within a shorter timeframe gives providers greater flexibility to respond…...

The Manila Times
manilatimes. net > 04/07/2026 > tmt-newswire > globenewswire > everbright-health-announces-ai-enabled-platform-to-unlock-access-to-advanced-mental-health-interventions > 2315328

Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions

1+ week, 10+ hour ago  (264+ words) The Manila Times New Platform Streamlines Path from Eligibility to Care for Patients Who Are Resistant to Standard Treatments SAN FRANCISCO, April 07, 2026 (GLOBE NEWSWIRE) -- Everbright Health, an AI-enabled services platform that helps mental health providers deliver advanced interventions as part…...

The Manila Times
manilatimes. net > 03/30/2026 > tmt-newswire > globenewswire > bd-releases-largest-multimodal-psychiatric-dataset-to-accelerate-breakthroughs-in-bipolar-disorder > 2310676

BD" Releases Largest Multi'Modal Psychiatric Dataset to Accelerate Breakthroughs in Bipolar Disorder

2+ week, 1+ day ago  (304+ words) New integrated dataset combines clinical, biological, neuroimaging, and real'world behavioral data to transform understanding and improve care for people living with bipolar disorder. Washington, D. C. , March 30, 2026 (GLOBE NEWSWIRE) -- Unprecedented Scale and Depth The release includes data from 615 participants from the initial…...

The Manila Times
manilatimes. net > 03/25/2026 > tmt-newswire > globenewswire > gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd > 2307779

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

2+ week, 6+ day ago  (113+ words) "Publication in JAMA Psychiatry provides independent peer-reviewed validation of our Phase 2b findings," said Dr. Velichka Valcheva, Chief Executive Officer. "This supports our ongoing efforts to advance GH001 into global pivotal trials." New Finding: GH001 Efficacy Is Independent of Prior Treatment Failures A…...

The Manila Times
manilatimes. net > 03/24/2026 > tmt-newswire > globenewswire > probing-and-rescuing-dysfunctional-brain-circuits-in-depression > 2306754

Probing and Rescuing Dysfunctional Brain Circuits in Depression

3+ week, 6+ hour ago  (229+ words) The Manila Times Probing and Rescuing Dysfunctional Brain Circuits in Depression A Free Webinar From The Brain & Behavior Research Foundation Conor Liston, M. D. , Ph. D. The guest speaker, Conor Liston, M. D. , Ph. D. , is a professor of psychiatry, developmental psychobiology and neuroscience at Weill…...

manilatimes. net
manilatimes. net > 01/08/2026 > tmt-newswire > globenewswire > ontario-shores-launches-north-americas-first-recovery-high-school-program-for-youth-mental-health > 2255621

Ontario Shores Launches North America's First Recovery High School Program for Youth Mental Health

3+ mon, 6+ day ago  (373+ words) Whitby, Ontario, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ontario Shores Centre for Mental Health Sciences (Ontario Shores) has opened North America's first'Recovery High School, giving students with mental health challenges a way to stay in school while receiving therapeutic support. The voluntary, course-based…...

The Manila Times
manilatimes. net > 12/10/2025 > tmt-newswire > globenewswire > idorsias-treatment-for-insomnia-disorder-wins-the-inaugural-prix-galien-bridges-award-in-the-best-biotechnology-pharmaceutical-product-category > 2240214

Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the "Best Biotechnology & Pharmaceutical Product' category

4+ mon, 5+ day ago  (455+ words) Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of "Best Biotechnology & Pharmaceutical Product. The award recognizes groundbreaking medicines, including biologics, gene therapies, and traditional…...

The Manila Times
manilatimes. net > 11/19/2025 > tmt-newswire > globenewswire > neurosigma-launches-next-generation-monarch-device-for-pediatric-adhd-after-successful-pilot-program > 2226740

Neuro Sigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program

4+ mon, 3+ week ago  (389+ words) Company dispensed over 1, 000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch. .. Neuro Sigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program Company dispensed over 1, 000 FDA-cleared systems in pilot phase; unveils new…...

The Manila Times
manilatimes. net > 10/20/2025 > tmt-newswire > globenewswire > spark-biomedical-awarded-an-nih-grant-to-study-the-treatment-effects-of-tan-for-alcohol-withdrawal-symptoms > 2204373

Spark Biomedical Awarded an NIH Grant to Study the Treatment Effects of t AN" for Alcohol Withdrawal Symptoms

5+ mon, 3+ week ago  (159+ words) STTR Phase I AUD study to be conducted in partnership with Menninger Clinic and Baylor College of Medicine Securing this NIH/NIAAA award amid today's competitive funding environment is especially meaningful. Spark Biomedical is grateful for the unwavering dedication of…...

The Manila Times
manilatimes. net > 09/23/2025 > tmt-newswire > globenewswire > atai-life-sciences-and-beckley-psytech-report-positive-phase-2a-data-demonstrating-improved-outcomes-with-a-two-dose-induction-regimen-of-bpl-003-in-patients-with-treatment-resistant-depression > 2188847

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

6+ mon, 3+ week ago  (167+ words) Dosing and follow-up in the open-label extension (OLE) stage of the Phase 2b study, which is evaluating the effects of a 12 mg dose of BPL-003 administered eight weeks after the initial dose in the core study, is complete and data are…...